Eosinophil cationic protein mRNA expression in children with bronchial asthma

Yu, Haiyue; Li, XY; Zf, Cai; L, Li; Xz, Shi; Hx, Song; Xj, Liu

doi:10.4238/2015.november.13.11

Cited by 5 publications

(4 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Bronchial asthma is a chronic inflammatory airway disease involving eosinophils, mast cells, neutrophils, and airway epithelial cells ( 1 – 4 ), and is a common chronic respiratory disease, which seriously endangers human health. The pathogenesis of bronchial asthma is very complicated.…”

Section: Introductionmentioning

confidence: 99%

Epigallocatechin gallate improves airway inflammation through TGF‑β1 signaling pathway in asthmatic mice

et al. 2018

View full text Add to dashboard Cite

The present study aimed to investigate the effect of epigallocatechin gallate (EGCG) on airway inflammation in mice with bronchial asthma, and the regulatory mechanism of transforming growth factor (TGF)-β1 signaling pathway, so as to provide theoretical basis for research and development of a novel drug for clinical treatment. Mouse models of bronchial asthma were established and injected with dexamethasone and EGCG via the caudal vein. 7 days later, bronchoalveolar tissue was collected for hematoxylin and eosin staining. Determination of airway resistance (AWR) and lung function in mice was detected. Serum was separated for cytometric bead array to detect the changes in inflammatory factors. Bronchoalveolar lavage fluid was collected for eosinophil and neutrophil counts. Fresh blood was obtained for flow cytometry to determine the percentages of Th17 and Treg cells. Bronchovesicular tissue was utilized for western blot assay and reverse transcription-quantitative polymerase chain reaction to determine the proteins and transcription factors in the TGF-β1 pathway. EGCG 20 mg/kg significantly reduced asthmatic symptoms, lung inflammatory cell infiltration, and the inflammatory factor levels of interleukin (IL)-2, IL-6 and tumor necrosis factor (TNF)-α. In addition, it increased the levels of inflammatory factors, including IL-10, diminished the percentage of Th17 cells, increased the percentage of Treg cells, and decreased the expression of TGF-β1 and phosphorylated (p)-Smad2/3 expression. Following the inhibition of the TGF-β1 receptor, the anti-inflammatory effect of EGCG disappeared, and the expression of TGF-β1 and p-Smad2/3 increased. EGCG attenuated airway inflammation in asthmatic mice, decreased the percentage of Th17 cells and increased the percentage of Treg cells. The anti-inflammatory effect of EGCG is achieved via the TGF-β1 signaling pathway.

show abstract

Section: Introductionmentioning

confidence: 99%

Epigallocatechin gallate improves airway inflammation through TGF‑β1 signaling pathway in asthmatic mice

et al. 2018

View full text Add to dashboard Cite

show abstract

“…Bronchial asthma is a chronic inflammatory respiratory disease that seriously affects human health ( 1 ). It develops from a chronic airway inflammation that involves eosinophils, lymphocytes, mast cells, neutrophils and other inflammatory cells and cell components ( 2 – 4 ). Approximately 300 million people worldwide currently suffer from asthma.…”

Section: Introductionmentioning

confidence: 99%

Vitaminï¿½D reduces inflammatory response in asthmatic mice through HMGB1/TLR4/NF‑κB signaling pathway

et al. 2017

View full text Add to dashboard Cite

The present study aimed to investigate the effects of vitamin D (VD) on inflammatory responses in asthmatic mice and the underlying mechanism, providing a theoretical basis for clinical application of targeted drug therapy, and the development of novel drugs against asthma. Mouse models of asthma were established. Hematoxylin-eosin staining was performed to observe the pathological changes of the lung tissue. Pulmonary function tests were conducted to determine airway resistance in asthmatic mice. ELISA was performed to measure the serum levels of inflammatory factors. Western blot analysis and reverse transcription-quantitative polymerase chain reaction were performed to determine the changes in apoptosis-inducing factors, and high mobility group box 1 protein (HMGB1)/Toll-like receptor-4 (TLR4)/nuclear factor (NF)-κB signaling pathway-related proteins. VD reduced infiltrated inflammatory factors, attenuated the airway resistance of asthmatic mice, decreased serum levels of interleukin (IL)-1β, IL-6, tumor necrosis factor (TNF)-α, increased serum levels of IL-10, decreased apoptotic factor Bcl-2-associated X and caspase-3 expression, downregulated HMGB1 and TLR4, NF-κB and phosphorylated-NF-κB p65 expression. When TLR4 expression was inhibited, the anti-inflammatory effects of VD were attenuated, and HMGB1, TLR4, NF-κB and p-NF-κB p65 expression was increased. VD was able reduce the inflammatory response of asthmatic mice and apoptosis in lung tissue through the HMGB1/TLR4/NF-κB signaling pathway.

show abstract

“…Asthma is a complex chronic airway disease caused by multiple factors. With in-depth research on its pathogenesis, it is recognized that its essence is a chronic non-specific inflammation mediated by a variety of cells and cytokines, with the characteristics of high airway reactivity and reversible airflow restriction [ 12 – 14 ]. The present study shows that asthma patients have increased respiratory tract cholinergic nerve tension.…”

Section: Discussionmentioning

confidence: 99%

Therapeutic Effects of a Long-Acting Cholinergic Receptor Blocker, Tiotropium Bromide, on Asthma

et al. 2018

View full text Add to dashboard Cite

Background The aim of this study was to evaluate the therapeutic effects of tiotropium bromide on asthma. Material/Methods A total of 160 patients with moderate persistent asthma were randomly divided into 4 groups (n=40): the 3 control groups were given fluticasone propionate aerosol (group A), salmeterol-fluticasone propionate inhalant (group B), and tiotropium bromide inhalation powder combined with salmeterol-fluticasone propionate inhalant (group C), respectively, and the experimental group received tiotropium bromide inhalation powder combined with fluticasone propionate aerosol (group D) and salbutamol was used to relieve symptoms when necessary. Results After 8 weeks of treatment, the pulmonary function of group D, which was significantly better than those of group A (P<0.05), was similar to those of groups B and C (P>0.05). Group D had significantly better asthma control test scores and nighttime symptom scores than in group A (P<0.05), without significant differences from those of group B or group C (P>0.05). The number of times salbutamol was used to alleviate symptoms was significantly different (P<0.05) between group D and group A (P<0.05), as well as between group C and group D (P<0.05). Groups D and B had similar results (P>0.05). IL-13 levels in induced sputum had significant differences (P<0.05). The levels in group D, which were higher than those of groups A and B (P<0.05), were similar to those of group C (P>0.05). Conclusions Tiotropium bromide combined with fluticasone propionate improved the respiratory function and quality of life, and is a new therapy for moderate, persistent asthma.

show abstract

Eosinophil cationic protein mRNA expression in children with bronchial asthma

Cited by 5 publications

References 25 publications

Epigallocatechin gallate improves airway inflammation through TGF‑β1 signaling pathway in asthmatic mice

Epigallocatechin gallate improves airway inflammation through TGF‑β1 signaling pathway in asthmatic mice

Vitaminï¿½D reduces inflammatory response in asthmatic mice through HMGB1/TLR4/NF‑κB signaling pathway

Therapeutic Effects of a Long-Acting Cholinergic Receptor Blocker, Tiotropium Bromide, on Asthma

Contact Info

Product

Resources

About